Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 154

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 154
---
NewGenIvf’s major suppliers are pharmaceutical companies.

Competition

NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:

| ● | the value and comprehensiveness of the solutions; |

| ● | treatment that is effective and achieves desired outcomes; |

| ● | clients’ experience, including dedicated patient education, clinical 
 guidance and emotional support; and                                  |

| ● | access to a network of high-quality fertility specialists. |

NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf’s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.

As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject
to additional competition.

Facilities

As of December 31, 2024,
in addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for
its administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network
of Facilities” above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.

<div align='center'>90

SELLING SECURITYHOLDER</div>

This prospectus relates
to the possible resale from time to time by the Selling Securityholders of up to 22,027,500 Class A Ordinary Shares, which includes (i)
12,500 Class A Ordinary Shares issued to Genetics and IVF Institute pursuant to the MicroSort Purchase Agreement; (ii) 15,000 Class A
Ordinary Shares issued to ASPAC pursuant to the Consulting Services Agreement; (iii) 12,000,000 Class A Ordinary Shares issuable upon
the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024
(“Exchange Notes”), (c) the exercise of Series A warrants to purchase Class A Ordinary Shares (the “Series A Warrants”),
(d) the exercise of Series B warrants to purchase